Clinical Trial Update: A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Roche investigational agents Lomvastomig and Tobemstomig with nivolumab in advanced or metastatic esophageal squamous cell carcinoma has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Lomvastomig (lomvastomig)
• Tobemstomig
• nivolumab (nivolumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Advanced or Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2026-03-27